DGAP-News

Epigenomics AG announces 2017 First Quarter Financial Results - Seite 3

www.epigenomics.com/en/news-investors/investors/financial-reports.html

Conference call for analysts and investors

The Company will host a conference call and webcast at 4.00 pm CET / 10.00 am EDT, today. The presentation can be followed on the Company's website.

The dial-in numbers for the conference call are:

Germany: [phone]

UK: [phone]

USA: [phone]

A transcript of the conference call will be provided on Epigenomics' website subsequently: http://www.epigenomics.com.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.

For more information, visit www.epigenomics.com.

Contact:

Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel [phone], Fax [phone], E-Mail: [e-mail]

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.